Treatments

The family of substances (cannabinoids) in Cannabis are currently being highly researched as neuroprotective agents

Alzheimer

Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines [Internet]. (2019)

Abstract

Dementia refers to a set of symptoms and signs associated with a progressive deterioration of cognitive functions that affects daily activities. Symptoms may include memory loss and difficulties with thinking, problem-solving or language, as well as changes in mood, perception, personality, or behaviour. According to the World Alzheimer Report 2018, about 50 million people worldwide lived with dementia in 2018, with the number projected to increase to 152 million by 2050[…]

Author Information

Peprah K, McCormack S.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.

Cannabis Therapeutics and the Future of Neurology. (2018)

Abstract

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain[…]

Author Information

Russo EB.

International Cannabis and Cannabinoids Institute (ICCI), Prague, Czechia.

Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease. (2019)

Abstract

Here we demonstrate for the first time that cannabidiol (CBD) acts to protect synaptic plasticity in an in vitro model of Alzheimer’s disease (AD). The non-psychoactive component of Cannabis sativa, CBD has previously been shown to protect against the neurotoxic effects of beta amyloid peptide (Aβ) in cell culture and cognitive behavioural models of neurodegeneration[…]

Author Information

Hughes B, Herron CE.

School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin 4, Ireland. School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin 4, Ireland. Caroline.Herron@ucd.ie.

Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. (2017)

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease, in which the primary etiology remains unknown. AD presents amyloid beta (Aβ) protein aggregation and neurofibrillary plaque deposits. AD shows oxidative stress and chronic inflammation. In AD, canonical Wingless-Int (Wnt)/β-catenin pathway is downregulated, whereas peroxisome proliferator-activated receptor γ (PPARγ) is increased[…]

Author Information

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Experimental and Clinical Neurosciences Laboratory, INSERM U1084, University of Poitiers, Poitiers, France. Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, Poitiers, France. Centre de Recherche Clinique, Hôpital de Meaux, Meaux, France. Université de Poitiers et CHU de Poitiers, DACTIM, Laboratoire de Mathématiques et Applications, UMR CNRS 7348, SP2MI, Futuroscope, France. CHU Amiens Picardie, Université Picardie Jules Verne (UPJV), Amiens, France.

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. (2017)

Abstract

Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do not stop or reverse the disease progression, highlighting the need for new, more effective therapeutics. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective[…]

Author Information

Watt G, Karl T.

Karl Group, Behavioural Neuroscience, Western Sydney University Campbelltown, NSW, Australia. Karl Group, Behavioural Neuroscience, Western Sydney University Campbelltown, NSW, Australia; Neuroscience Research Australia Randwick, NSW, Australia.

Treatments
_